Objectives: Healthcare-associated infections due to third-generation cephalosporin-resistant Enterobacteriaceae (CRE) have become a major public health threat, especially in intensive care units (ICUs). We assessed and compared b-lactam use, the prevalence of colonization with CRE at admission and the incidence of CRE acquisition across ICUs.
Introduction
For the past 20 years, healthcare-associated infections (HAIs) caused by antibiotic-resistant Gram-negative pathogens, especially extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae, have become a problem 1,2 with possibly serious consequences, such as enhancing the negative aspect of the prognosis of the infection 3 and even increasing the lethality of the infection. 4 -6 In France, the overall prevalence of HAIs was estimated at 4.3% of all hospitalizations in 2006, but was as high as 24% in intensive care units (ICUs). 7 Enterobacteriaceae were responsible for .43% of all HAIs, showing reduced susceptibility to third-generation cephalosporins in almost 15% of these. 7 In ICUs, third-generation cephalosporin-resistant Enterobacteriaceae (CRE) represented .20% (for ESBL producers specifically, from 7% in 2006 to 13% in 2007) of Enterobacteriaceae isolated from clinical specimens. 8 Numerous epidemiological studies have identified individual antibiotic exposure, more specifically exposure to b-lactams, as an independent risk factor for colonization or infection with CRE. 9 -12 Antibiotic prescriptions are especially frequent in ICUs, being generated for as many as 49% of patients on a single day compared with 16% in French hospitals overall in 2006. 7 b-Lactams were by far the most prevalent, accounting for 52% of all antibiotics that were prescribed, including 33% penicillins and 12% third-generation cephalosporins. 7 To our knowledge, however, hardly any previous studies have prospectively investigated the patterns of intestinal colonization with CRE and antibiotic use in a multicentre study of ICU patients. 13 The ColoRea [Colonisation en Réanimation (Colonization in Intensive Care)] study investigated the dynamics of intestinal colonization with CRE in ICU patients treated with b-lactams. The present paper describes its design and methods and the data that were collected. More specifically, we report findings about the patients' clinical characteristics, the prevalence of colonization at admission and the incidence of CRE acquisition, as well as patterns of antibiotic use in each ICU. (Table 1 ; see the footnotes for the locations of the ICUs). Three of the 10 ICUs were medical and 2 were surgical, while the remaining were mixed medico-surgical ICUs. The units had 8 -30 beds, most of which were located in private rooms (the exceptions included 2 double rooms in ICU9, 4 double rooms in ICU5 and 2 triple rooms in ICU1). Most units had internal guidelines for the prevention of HAIs and antibiotic use. An institutional review board approved the study protocol (CCPPRB 05023 St Germain en Laye); all patients were informed about the study goals and were asked to give consent for data collection.
Patients and methods

Study design and recruitment
Clinical information and biological samples were obtained from each patient present at the start of the study, or newly admitted afterwards, until the end of the study period in each ICU (n¼948; Figure 1) . Of all the patients admitted, 21 (2.2%) were excluded a priori without having provided consent. Among the remaining 927, we identified 30 patients who were admitted twice and two patients who were admitted three times to the same ICU during the study period. Only first-time admissions were considered, so that finally 893 distinct patients were recruited for the ColoRea study.
Microbiological surveillance and molecular analysis
Rectal swabs were obtained on admission and twice weekly thereafter. Additional swabs were obtained before any b-lactam prescription and before the patients were discharged. The specimens collected were inoculated on a biplate containing two selective media: MacConkey agar supplemented with 2 mg/L ceftazidime and Drigalski agar supplemented with 1.5 mg/L cefotaxime (medium AEB 525770, AES Laboratory, Combourg, France). Isolates that grew on the selective media were first analysed locally in the microbiology laboratory attached to each ICU for antimicrobial susceptibility. Following the criteria of the CLSI, 14 CRE were defined as isolates showing decreased susceptibility to ceftazidime (diameter ≤17 mm) or cefotaxime (diameter ≤22 mm), or producing ESBL. ESBL strains were detected by the disc diffusion method using the double disc synergy test with ceftazidime and cefotaxime (ceftazidime and cefepime for the group 3 natural AmpC producers), as recommended by the Antibiogram Committee of the French Society for Microbiology (www.sfm-microbiologie.org). Group 3 of Enterobacteriaceae included natural AmpC producers such as Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, Citrobacter braakii, Morganella morganii, Serratia marcescens and Hafnia alvei. 15 Clinicians had access to all results of the analyses that were performed locally.
All analysed strains were then centralized in a single laboratory (Tenon Hospital, Paris, France) for confirmation of identification using the API20E system (bioMérieux, Marcy l'Étoile, France). Further antibiotic susceptibility testing was also performed, in particular using the cefepimeclavulanate ESBL Etest. For molecular analyses, DNA was extracted using the Qiagen Mini Kit (Qiagen, Courtaboeuf, France). Detection of gene sequences coding for ESBLs and plasmid-mediated AmpC b-lactamases was performed by PCR using oligonucleotide primer sets reported previously. 16, 17 Positive PCR products were subjected to direct sequencing on both strands using PCR primers and results were analysed with the BLAST and ClustalW programs (www.ncbi.nlm.nih.gov). The clonality of all CRE strains, including all those isolated from the same sample of a given patient, was assessed by repetitive extragenic palindromic sequence PCR using primers rep-1R and rep-2T, and enterobacterial repetitive intergenic consensus sequence PCR using primer ERIC-2 as previously described. 18 
Data collection
For all recruited patients, medical staff collected standardized, detailed information on the patient's age, gender, reason for hospitalization, severity of illness according to the simplified acute physiology score (SAPS)-II, 19 McCabe's underlying disease score, 20 previous chronic health status (Knaus) , 21 sequential organ failure assessment (SOFA), 22 Glasgow coma score, 23 immunodeficiency, history of hospitalization within the year preceding admission and history of surgical procedures and antimicrobial therapy within the past 3 months. Further information was collected twice weekly thereafter to update the SOFA score and obtain information on antimicrobial therapy, parenteral nutrition, mechanical ventilation, central venous catheter use, etc. At the date of the patient's discharge, the reason for discharge was recorded.
Statistical analysis
The length of a patient's stay in the ICU was calculated as the difference between the date of discharge and the date of admission plus 1 day. Patient-days of follow-up started from admission or study start, whichever occurred last, and ended at discharge or study end, whichever occurred first. Unless otherwise specified, patients' characteristics were reported by centre in terms of percentages, medians and IQRs because most variables were not normally distributed. Distributions were compared between patients already present in the ICUs and those newly admitted using the x 2 test or Fisher's exact test for categorical variables and Wilcoxon's non-parametric test for continuous variables. We did not attempt testing across the ICUs due to limited sample size per ICU compared with the large number of ICUs.
To assess antibiotic use, we aggregated drug therapy data at the level of the active substance, in accordance with the Anatomic Therapeutic Chemical (ATC) classification and calculated corresponding defined daily doses (DDDs) based on WHO methodology (www.whocc.no/ atcddd/). Antibiotic use was restricted to ATC class J01. Exposure to antibiotics at the ICU level was expressed as DDDs/1000 patient-days.
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In the calculation of rates of colonization on admission and acquired colonization with CRE, we restricted our population to patients who were newly admitted and had their first specimen collection within 48 h after ICU admission. Patients whose first culture was negative were defined as 'naive'. Incidence rates of colonization with CRE were computed as the ratio of the number of naive patients who acquired CRE during their ICU stay to the total patient-days of follow-up of all naive patients. 24 Ecological correlations across the ICUs were examined using Spearman's correlation coefficient. Analyses were performed using Stata software (release 9.2, StataCorp, College Station, TX, USA).
Results
Patient recruitment and characteristics
When inclusions began, 100 patients (11.2%) had already been present in the ICU, for a median of 10 days before study start (IQR 4 -20 days). Among the 793 newly admitted patients (median age 59 years; Table 1 ), the median length of stay in the ICU was 5 days (IQR 3 -11; mean 8.7 days); 23.5% of the patients stayed for ,48 h. Most patients (80.7%) were admitted for medical reasons, except for the surgical ICUs, especially ICU6, close to a trauma centre. From 17% to 75% of patients directly originated from another ward or hospital. The median SAPS-II was 40 and the median SOFA score was 5 at admission, although patients in ICU8 tended to have more severe conditions. The proportion of immunocompromised patients was 26.2% overall, but was much higher in ICU1 (52.8%). Reasons for immunodeficiency included haematological malignant diseases or cancer and their treatment (55.9%), other immunosuppressive therapy (25.7%) and infection with HIV (18.3%). Within the 3 months preceding ICU admission, 17.2% patients had undergone surgery (45.5% in the surgical ICU8), while the proportion of patients who had been treated with antibiotics varied from 25.4% in ICU6 to 57.0% in ICU8.
After the initial evaluation, 3518 follow-up visits were performed during the study period. Among the newly admitted patients, a majority (64.9%) received mechanical ventilation at least once. In total, 50.3% had a central venous catheter, 49.0% were prescribed a proton pump inhibitor and 40.0% catecholamines, and 13.5% were administered parenteral nutrition and 15.4% dialysis.
Patients already hospitalized in the ICUs did not differ from newly admitted patients in terms of age distribution, gender, immunodeficiency, location and therapy before ICU admission (Table 1 ). However, already present patients tended to be more severe in terms of SAPS-II (median 45) and SOFA and McCabe's scores, as well as therapies received (central venous catheter 59.0%, proton pump inhibitor 57.0%, parenteral nutrition 23.0%).
In total, 159 patients (18.2/1000 patient-days) died during their ICU stay, of whom 51 (32.1%) died as a consequence of an infection (bacteraemic sepsis in 19, pneumonia in 13, intra-abdominal infection in 10, septic shock or multiple organ failure in 4 and other infection in the remaining 5).
Sample collection and colonization with CRE
Throughout the follow-up period, 3453 swab specimens were obtained from 888 (99.4%) recruited patients. More than half (51.2%) of the patients provided three or more specimens and Thiébaut et al.
the median time lag between two consecutive collections was 3 days in all ICUs (IQR 2 -4). Of the 945 strains that grew on the selective media, 895 (94.7%) were available for further microbiological analyses. Of the 793 newly admitted patients (excluding those already present), 5 were not sampled and 20 had their first swab collection .48 h after admission (Figure 1) . Among the remaining, the colonization rate on admission was 9.6% (74/768). Although all centres were concerned, the proportion of patients colonized on admission varied from 1.9% in ICU6 to 16.3% in ICU5 (Table 2) . Thirty-two of these isolates (43.2%) were ESBL producers and two were plasmid-mediated AmpC producers. Escherichia coli (n¼ 30, including 21 ESBL producers with 14 CTX-M producers and 1 CMY-2 producer), E. cloacae (n¼19, including 3 ESBL producers and 16 with stable AmpC derepression) 15 and Klebsiella pneumoniae (n¼ 6, including 5 ESBL producers and 1 DHA-1 producer) accounted for the majority of bacterial species isolated. Interestingly, ICUs with a high prevalence of ESBL-producing CRE on admission also tended to show a high prevalence of non-ESBL producers (Spearman's coefficient 0.72, P ¼ 0.02).
Of the 694 patients who were naive on admission, 94 (13.5%) acquired CRE during their subsequent ICU stay, a median of 7 days after their admission (IQR 3-11; mean 9). Thirty-one of these CRE (33.0%) were ESBL producers and two were plasmidmediated AmpC producers. In addition to E. cloacae (n¼ 32, including 5 ESBL producers and 27 with stable AmpC derepression), 15 K. pneumoniae (n¼ 15, all ESBL producers with 10 CTX-M), E. coli (n¼ 13, including 8 ESBL producers with 7 CTX-M producers, 2 CMY-2 producers and 3 AmpC hyperproducers) 15 and Citrobacter sp. (n¼ 18 including 1 ESBL producer and 17 with stable AmpC derepression) 15 were found most often. The incidence rate of acquisition for all CRE was 16.1/ 1000 patient-days overall, ranging from 8.8/1000 patient-days in ICU3 to 21.0/1000 patient-days in ICU7. We observed that incidence rates for ESBL-producing CRE were highest (9.3 -10.9/ 1000 patient-days) in three ICUs where this phenotype prevailed, mostly driven by K. pneumoniae (four out of seven strains in ICU1, six out of seven in ICU4 and three out of four in ICU5). Nevertheless, no statistically significant inverse correlation between incidence rates for ESBL and non-ESBL producers was found (Spearman's coefficient 20.47, P ¼ 0.17). Moreover, incidence rates were modestly, not statistically significantly, correlated to prevalence rates at admission. Of note, two major epidemics occurred during the study period, both of which were due to ESBL-producing K. pneumoniae. The same CTX-M-15 clone spread to 13 patients in ICU4, beginning with one who was already present at the study start and later concerning six incident colonization cases and one colonization at admission (as reported in Table 2 ; the remaining patients are not accounted for in Table 2 because they were already present in the ICU at the start of the study, or already colonized with another strain before acquiring the clonal strain, which corresponded to exclusion criteria for the main analysis, as described in Figure 1 ). Seven patients in ICU5, including the three incident cases reported in Table 2 , shared the same TEM-21 clone that was first isolated 7 days after study start (17 days after the patient's admission). Fourteen other episodes of cross-transmission were limited to 2 to 4 patients (involving a total of 5 patients colonized at admission and 13 cases of incident CRE acquisition): six episodes with E. cloacae (14 patients in ICU2, ICU3, ICU4, ICU5, ICU7 and ICU10, all non-ESBL-producing strains with stable AmpC derepression), three episodes with E. coli (7 patients in three ICUs, one non-ESBL-producing strain with TEM-1 in ICU1 and two ESBL-producing strains in ICU2, one with CTX-M-15 and TEM-1 and the other with CTX-M-1 and TEM-1) and one episode each of Klebsiella oxytoca (3 patients, CTX-M-9 and SHV-12 in ICU2), E. aerogenes (2 patients in ICU6), C. freundii (2 patients in ICU4), M. morganii (3 patients in ICU7) and H. alvei (2 patients in ICU2).
Antibiotic use
Most patients were prescribed antibiotics during their hospitalization (72.5%), in most cases within 48 h of admission (for 86.7% of them). Among these, 43.9% received combination therapy for at least 1 day. The average number of DDDs/1000 patient-days for all antibiotics combined was 1338, ranging from 865 in ICU3 to 1980 in ICU1 (Figure 2a) . Our major antibiotic class of interest, namely the b-lactams, was used in 68.3% of patients, accounting for an average of 756 DDDs/1000 patient-days (range 428 -985). Among the b-lactams (Figure 2b) , penicillins (J01CA) were used most, with an average of 262 DDDs/1000 patient-days; the third-generation cephalosporins (J01DD, 127 DDDs/1000 patient-days) and carbapenems (J01DH, 99 DDDs/ 1000 patient-days) came next.
We observed that the correlations between antimicrobial consumption and incidence rates were generally stronger for ESBLproducing CRE (Table 3) ICU1  ICU2  ICU3  ICU4  ICU5  ICU6  ICU7  ICU8  ICU9 ICU10   ICU1  ICU2  ICU3  ICU4  ICU5  ICU6  ICU7  ICU8  ICU9 Thiébaut et al.
cases of cross-transmission from all ICUs, those coefficients were 0.68, 0.75 and 0.59 (P¼ 0.029, 0.013 and 0.074).
Discussion
In this multicentre, prospective cohort of 893 patients, the 10 ICUs surveyed displayed varying practices in antimicrobial use and varying incidence rates of colonization with ESBL-and non-ESBL-producing CRE among naive patients. The ecological correlations between antibiotic prescriptions and incidence rates of colonization, which showed a positive association between b-lactam prescription and ESBL-producing CRE acquisition, are tantalizing. Overall, we estimated the incidence of acquisition to be 16.1/ 1000 patient-days for any CRE and 5.3/1000 patient-days for ESBL producers specifically. In France in 2007, the estimated incidence of ESBL-producing Enterobacteriaceae among patients hospitalized for at least 24 h was 1.04/1000 patient-days. 25 It was higher (1.63) in some ICUs in the Paris area, 25 but still lower than the figures reported here. However, in our study all patients were prospectively screened for colonization while only patients who had diagnostic samples collected were included in the previous French survey. 25 Using comparable methodology, our estimate is much closer to the 14/1000 patient-days CRE incidence reported in two Dutch ICUs. 13 In the Pan-European Antimicrobial Resistance using Local Surveillance study, 26 the prevalence of ESBL producers among Enterobacteriaceae was estimated at 5.2% in France in 2001 -02, mainly driven by E. aerogenes (27%), negligibly by E. cloacae (3%) and K. pneumoniae (,1%) and not at all by E. coli. We cannot directly compare these figures with those observed in our study because we did not assess all Enterobacteriaceae, but only those of the CRE phenotype; nevertheless, they seem to provide a different qualitative picture, with about a third of ESBL-producing CRE among incident isolates, mostly among K. pneumoniae and E. coli. Of note, ESBL-producing strains were predominantly of K. pneumoniae subspecies, at least in the three ICUs where ESBL producers prevailed over non-ESBL producers, with two of them (ICU1 and ICU5) having double or triple rather than only single rooms. The identification of two ESBL-producing K. pneumoniae circulating clones in two of these three ICUs (4 and 5) actually provided evidence for cross-colonization. Table 1 for the name and location of each ICU. 
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In the present study, 9.6% patients were found to be colonized with CRE on admission. Among them, 32 (4.2% of 768) carried an ESBL-producing strain, including 21 E. coli and 5 K. pneumoniae (3.4% in total). This finding is comparable to the prevalences reported in previously published studies. Thus, a 2% colonization rate with ESBL-producing E. coli or Klebsiella species was reported at admission to medical and surgical ICUs in the USA, 27 while an 8% prevalence of rectal carriage of ESBL-producing Enterobacteriaceae was observed at hospital admission in Israel. 28 Antibiotic use was rather frequent in the ICUs included in our study, consistent with the high consumption observed in France compared with other European countries. 29, 30 Thus, in their cross-national, retrospective comparison of antibiotic use in hospitals from 1997 to 2002, 30 the European Surveillance of Antimicrobial Consumption project reported broad variations across countries, France showing the highest total antibiotic use (3.9 DDDs/1000 inhabitants/day), three times higher than the lowest use (1.3 DDDs/1000 inhabitants/day in Norway and Sweden). Moreover, France displayed by far the highest use of b-lactams, with about 2.0 and 0.3 DDDs/1000 inhabitants/day for penicillins and cephalosporins, respectively. 30 As a reflection of the patient's infectious status at admission, antibiotic prescriptions were generated within the first 48 h in 62.8% of patients (86.7% of the 72.5% with prescriptions) in our study compared with 55.2% in a French nationwide survey of ICUs in 2007. 8 Our finding of high antibiotic use is consistent with the quite severe medical condition of the ICU patients included in the present study, as indicated by their health status scores and the frequencies of the invasive procedures undergone. For instance, ICU1, which showed the highest antibiotic use, had a noticeably greater proportion of immunocompromised patients and individuals referred from other wards or other hospitals. It has been suggested that variability in antibiotic use may be explained, at least partly, by differences in case mix across hospitals, consumption being likely to increase with the severity of illness. 31 Heterogeneity across units is not an uncommon finding. Indeed, another study comparing antibiotic use in 26 internal medicine departments of six Israeli hospitals in 2003-04 reported substantial variations in practices between hospitals within the same country, as well as between departments within the same hospital. 32 Analysing classes of antibiotics separately yielded even wider variations. 32 We also observed such heterogeneity and noted that ICUs ranked differently in terms of proportions of patients prescribed and DDDs, suggesting heterogeneity in doses and durations of treatment. When relating incidence rates of acquisition to antibiotic prescriptions, we found statistically significant associations for ESBL-producing CRE and all antibiotics, b-lactams and, less consistently, carbapenems. The correlation with carbapenem use was unexpected and is of concern as carbapenems are often considered a therapeutic option in the treatment of infections due to ESBL-producing Enterobacteriaceae. 33 Few authors have reported correlations between antimicrobial drug consumption and the acquisition of CRE at the hospital or department level. In their report of an outbreak of ceftazidime-resistant K. pneumoniae at the Cleveland Department of Veterans Affairs Medical Center, Rice et al. 34 found a strong correlation (0.81, the square root of 0.66, P ¼ 0.002) between total use of ceftazidime in year 2004 across six wards and their ranking in terms of prevalence rates of resistance to ceftazidime among K. pneumoniae isolates during the same year. The prevalence of ceftazidime-resistant K. pneumoniae significantly decreased after piperacillin/tazobactam was introduced and the use of ceftazidime was restricted, without instituting barrier precautions. 34 Comparing six departments of internal medicine of one university hospital in Israel for the period 1991-96, Leibovici et al. 35 reported a statistically significant positive association between departmental consumption of ceftazidime and infection with CRE. In contrast, comparing 14 departments of a tertiary care hospital in Greece for the period 2001 -04, Iosifidis et al. 36 did not find any association between median annual consumption of third-generation cephalosporins (range 1.0 -39.4 DDDs/100 bed-days) and the prevalence of ceftazidime resistance in K. pneumoniae and E. coli. The prevalence of resistance to third-generation cephalosporins was generally higher among K. pneumoniae isolates (.40% in eight departments) than among E. coli isolates (,20% in all but one department). The authors suggest that the lack of association may reflect crosstransmission, especially for K. pneumoniae, which showed a high prevalence of resistance even in departments with low antimicrobial consumption. 36 Examining temporal rather than ecological correlations, Harbarth et al. 37 found no association between annual ward-level consumption of third-generation cephalosporins and CRE percentage among Enterobacteriaceae. They advised caution in interpreting group-level data with respect to the impact of antimicrobial use on resistance acquisition in individual patients because of the possibility of ecological bias. 37 The strengths of the present study include its prospective design; numerous studies in the field are retrospective studies. 13 The prospective design allowed standardized collection of antibiotic, microbial and other clinical data. Moreover, the assessment of resistance to third-generation cephalosporins was performed in a central laboratory, making it possible to rule out differences in CRE incidence across centres due to varying assessment methods. However, a causal association between antibiotic use and CRE acquisition cannot be inferred from our ecological correlations. Indeed, any centre could have increased its use of antibiotics after detection of colonization with CRE in a number of patients. Such reverse causation could be an explanation for our finding of an association between carbapenem prescription and ESBL-producing CRE acquisition rates: instead of the rates increasing due to selective pressure by carbapenems, ICUs with high CRE prevalence could favour prescriptions of carbapenems instead of other b-lactams.
In conclusion, our study demonstrated strong disparities across ICUs in terms of colonization with CRE and ESBL strains, as well as in patterns of antibiotic use. Further support of the role of antimicrobial exposure in the dynamics of colonization with CRE is highlighted, and this may ultimately lead to the control of resistance diffusion.
